% | $
Quotes you view appear here for quick access.

Galena Biopharma, Inc. Message Board

  • troyanderson747 troyanderson747 Oct 11, 2012 10:01 AM Flag

    NeuVax worht BILLIONS and $4.00 target reiterated ...again

    Roughly 200 female patients were treated during the two phase 2 studies for NeuVax, and those who received the vaccine saw a 50% reduction in recurrence. The vaccine was even more effective when booster doses were utilized. This indicates that the vaccine can be used in several different ways, and thus, increases its market potential. The potential for billions in annual revenue resulted in one of the world's best-known capital markets investment banks, Cantor Fitzgerald, reiterating its "Buy" rating and a $4.00 price target for Galena Biopharma.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.45-0.02(-4.26%)Jul 22 4:00 PMEDT